Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy
Global contract development and manufacturing organisation (CDMO) Recipharm is partnering with Ahead Therapeutics to develop a ground-breaking treatment for a rare autoimmune disease, myasthenia gravis. Ahead Therapeutics is a Spanish start-up biotech company, using proprietary technology to develop treatments for different autoimmune disorders. Under the agreement, Recipharm will provide analytical and process development capabilities to support toxicology studies, as well as GLP manufacturing of lipid nanoparticles to encapsulate the active pharmaceutical ingredient, an antigen peptide.